Suffolkres
Senior Member (Voting Rights)
Just a few more interesting points...
Here is Haley's first paper about PON1, pyridostigmine and sarin (from 1999): https://pubmed.ncbi.nlm.nih.gov/10373407/
in which the abstract says: "A history of advanced acute toxicity after taking pyridostigmine was also correlated with low PON1 type Q arylesterase activity."
Pyridostigmine is used in advance of chemical nerve agent attack because it blocks the pathways that the nerve agents use. However, if it is used too late, once a person has already been exposed to sublethal amounts of nerve agent, it can exacerbate the effects of the agent.
I'm wondering whether the reason it [Mestinon] doesn't work for some as a treatment for POTS is because of their particular PON1 subtype and/or activity?
Maybe there's also an interaction with pesticides too (pet flea treatments)?
Not sure if findings here overlap?
https://academic.oup.com/jid/article/197/8/1171/903299?login=true
Gene Expression Subtypes in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
Jonathan R Kerr, Robert Petty, Beverley Burke, John Gough, David Fear, Lindsey I Sinclair, Derek L Mattey, Selwyn C. M Richards, Jane Montgomery, Don A Baldwin,
Paul Kellam, Tim J Harrison, George E Griffin, Janice Main, Derek Enlander, David J Nutt, Stephen T Holgate
The Journal of Infectious Diseases, Volume 197, Issue 8, 15 April 2008, Pages 1171–1184, https://doi.org/10.1086/533453